13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05482542 (ClinicalTrials.gov)	January 1, 2023	12/7/2022	Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosi ...	Optimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantationof Relap ...	Multiple Sclerosis, Relapsing-Remitting	Other: Autologous hematopoietic stem cell transplantation;Drug: Cyclophosphamide /ATG;Drug: Cyclophos ...	Scripps Health	NULL	Recruiting	18 Years	58 Years	All	200	N/A	United States
2	NCT04971005 (ClinicalTrials.gov)	August 27, 2021	12/8/2020	Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantationin Multip ...	A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic St ...	Relapsing-Remitting Multiple Sclerosis	Drug: Autologous Hematopoietic Stem Cell Transplantation;Drug: Ocrelizumab;Drug: Alemtuzumab	Universitätsklinikum Hamburg-Eppendorf	Neovii Biotech;Clinical Trial Center North (CTC North GmbH & Co. KG)	Recruiting	18 Years	55 Years	All	50	Phase 2	Germany
3	EUCTR2016-001166-29-DE (EUCTR)	18/03/2020	12/08/2019	A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic st ...	A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic st ...	relapsing-remitting multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Lemtrada Product Name: alemtuzumab INN or Proposed INN: alemtuzumab Other descriptive name: ...	University Medical Centre Hamburg-Eppendorf	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Germany
4	NCT04047628 (ClinicalTrials.gov)	December 19, 2019	5/8/2019	Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (B ...	A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic ...	Relapsing Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple S ...	Procedure: Autologous Hematopoietic Stem Cell Transplantation;Biological: Best Available Therapy (BA ...	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);Blood and Marrow Transplant Clinical Trials Network;PPD;Rho Federal S ...	Recruiting	18 Years	55 Years	All	156	Phase 3	United States;United Kingdom
5	EUCTR2017-001362-25-NL (EUCTR)	30/09/2019	10/09/2019	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantationversus alemtuzumab, cladribine or ocrel ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Denmark;Netherlands
6	EUCTR2017-001362-25-DK (EUCTR)	27/06/2018	21/03/2018	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantationversus alemtuzumab, cladribine or ocrel ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Sendoxane Product Name: Cyclophosphamide Trade Name: Thymoglobuline ® Product Name: Thymoglo ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Denmark;Netherlands
7	EUCTR2017-001362-25-SE (EUCTR)	02/05/2018	17/10/2017	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantationversus alemtuzumab, cladribine or ocrel ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Sendoxane Product Name: Cyclophosphamide Trade Name: Thymoglobuline ® Product Name: Thymoglo ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Denmark;Netherlands;Sweden
8	NCT03477500 (ClinicalTrials.gov)	March 21, 2018	13/2/2018	RCT Comparing Autologous Hematopoietic Stem Cell TransplantationVersus Alemtuzumab, Cladribine or Oc ...	Randomized Autologous heMatopoietic Stem Cell TransplantationVersus Alemtuzumab, Cladribine or Ocrel ...	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab;Drug: Cladribine Pill;Drug: Ocrelizumab	Haukeland University Hospital	NULL	Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
9	NCT03113162 (ClinicalTrials.gov)	May 29, 2015	10/4/2017	Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for M ...	Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoiet ...	Multiple Sclerosis	Biological: Autologous Hematopoietic Stem Cell;Drug: BEAM Regimen	Makati Medical Center	NULL	Recruiting	18 Years	60 Years	All	15	Phase 1	Philippines
10	NCT03133403 (ClinicalTrials.gov)	November 2013	21/4/2016	Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Thera ...	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate ...	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Tecfidera (BG12);Drug: Gilenya;Drug: Tysabri ®;Drug: Avonex /Betaseron/Copaxone/Rebif;Procedure: ...	Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Recruiting	18 Years	55 Years	All	5	Phase 2/Phase 3	United Kingdom

First Previous1 2Next Last